A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Buspirone/Zolmitriptan (Primary)
- Indications Drug-induced dyskinesia
- Focus Pharmacodynamics
- Acronyms SHINE
- Sponsors Bukwang Pharmaceutical
Most Recent Events
- 14 Jun 2024 Status changed from active, no longer recruiting to discontinued (due to business reasons).
- 07 Feb 2024 Planned number of patients changed from 188 to 148.
- 07 Feb 2024 Planned End Date changed from 17 Jul 2024 to 3 Jan 2025.